Edition:
India

Bellerophon Therapeutics Inc (BLPH.OQ)

BLPH.OQ on NASDAQ Stock Exchange Global Market

2.62USD
15 Dec 2017
Change (% chg)

$0.20 (+8.26%)
Prev Close
$2.42
Open
$2.45
Day's High
$2.68
Day's Low
$2.41
Volume
167,884
Avg. Vol
57,538
52-wk High
$2.68
52-wk Low
$0.48

Chart for

About

Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary... (more)

Overall

Beta: --
Market Cap(Mil.): $55.04
Shares Outstanding(Mil.): 35.51
Dividend: --
Yield (%): --

Financials

BRIEF-Bellerophon Appoints Ted Wang To Its Board Of Directors

* BELLEROPHON APPOINTS TED WANG, PH.D., OF PUISSANCE CAPITAL MANAGEMENT, TO ITS BOARD OF DIRECTORS

01 Dec 2017

BRIEF-Bellerophon Therapeutics reports Q3 loss per share $0.22

* Bellerophon provides business update and reports third quarter 2017 financial results

07 Nov 2017

BRIEF-Bellerophon Therapeutics says selling stockholders may offer, resell up to 38.9 mln shares - SEC filing

* Bellerophon Therapeutics Inc files to say selling stockholders may offer and resell up to 38.9 million shares of co's common stock - SEC filing

25 Oct 2017

BRIEF-Bellerophon announces $23 million private placement

* Bellerophon Therapeutics Inc - ‍financing was led by Puissance Capital Management and Venrock Healthcare Capital Partners​

27 Sep 2017

BRIEF-Bellerophon announces positive top line Phase 2 data of INOpulse

* Bellerophon announces positive top line Phase 2 data of INOpulse for treatment of Pulmonary Hypertension associated with Chronic Obstructive Pulmonary Disease

05 Sep 2017

BRIEF-Bellerophon reports Q2 loss per share $0.12

* Bellerophon reports second quarter 2017 financial results and provides business update

07 Aug 2017

BRIEF-Bellerophon announces FDA agreement on phase 2B study design for Inopulse

* Bellerophon announces FDA agreement on phase 2B study design for Inopulse in pulmonary hypertension associated with interstitial lung disease (PH-ILD)

03 Aug 2017

Earnings vs. Estimates